Project Detail

Oral Vaccine To Inhalation Rabies

Project Number: 5R01AI055018-03 Source: National Institutes of Health
Principal Investigator: Hildegund C. J. Ertl Organization: Wistar Institute
Project Duration: 07/15/2004 - 12/31/2008 Fiscal Year: 2006
Recovery Act: No   No Award: $452,413

Application Type: Non-competing Continuation
Funding Institution: National Institute of Allergy and Infectious Diseases
Activity: Research Project
Year of Support: 3

DESCRIPTION (provided by applicant): The application has the goal to develop an improved vaccine to rabies virus that provides protection upon a single dose given orally or intranasally against a severe form of inhalation challenge such as with weaponized rabies virus. We have developed an El-deleted adenoviral recombinant derived from a chimpanzee isolate. This adenoviruses (Ad) of the C68 serotype (AdC68) does not circulate in the human population and virus neutralizing antibodies (VNAs) to common human serotypes of Ad fail to cross-react with AdC68 virus. Vaccines based on AdC68 virus, such as the one expressing the rabies virus glycoprotein ( are thus not impaired by natural exposure of a human population to most common human serotypes of Ad.
In aim 1, the biodistribution of the vaccine upon oral and intranasal application into mice will be tested. It will be established if oral or intranasal immunization with the vaccine protects against inhalation rabies and which immune effect mechanisms (serum or mucosal VNAs or frequencies of rabies virus specific B cells in nasal associated lymphoid tissues, spleens or lungs) correlate with protection. The longevity of vaccine-induced protection will be determined. Efficacy of the mucosal vaccine will be assessed in immunologically challenged animals such as infant or aged mice and mice lacking CD4+ T cells. In aim 2, the vaccine will be tested in a non-human primate rabies virus challenge model.

Project Number Project Title Organization Principal Investigator Fiscal Year Total Award
1R01AI055018-01A1 Oral Vaccine To Inhalation Rabies Wistar Institute Hildegund C. J. Ertl 2004 $228,001
5R01AI055018-02 Oral Vaccine To Inhalation Rabies Wistar Institute Hildegund C. J. Ertl 2005 $382,808
Page 1 of 1 (2 items)